CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia
Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This study is designed to explore the safety and efficacy of CD7 CAR-T Cells for patients
with relapse/refractory CD7+ NK/T cell lymphoma ,T-lymphoblastic lymphoma and Acute
Lymphocytic Leukemia. And to evaluate the pharmacokinetics of CD7 CAR-T cells in patients.
Phase:
Phase 1
Details
Lead Sponsor:
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Collaborator:
The First Affiliated Hospital of Zhengzhou University